This inventor holds 29 USPTO granted patents and 20 published patent applications and 9 EPO patents, primarily in Oligonucleotide Therapeutics. Top assignees: Sarepta Therapeutics, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services, The University of North Carolina at Chapel Hill. Active years: 1997-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Orange County, NC (US) (1997)
- Chapel Hill, NC (US) (1997 - 2015)
- Bellevue, WA (US) (2014 - 2016)
- Corvallis, OR (US) (2011 - 2022)
- Cambridge, MA (US) (2020 - 2023)
Company Filing History:
23 out of 127 
5 out of 3,693 
5 out of 1,326 
Years Active: 1997-2023
Areas of Expertise:
Title: The Inventive Journey of Ryszard M Kole: Pioneering Antisense Therapeutics
Introduction:
Ryszard M Kole, a distinguished inventor in the field of molecular biology and therapeutics, has made significant contributions to the development of antisense oligonucleotide technologies. With a strong background in research and a passion for innovation, he has accumulated an impressive portfolio of 28 patents. Based in Chapel Hill, NC (US), Kole's work has had a profound impact on the treatment of genetic disorders and rare diseases.
Latest Patents:
Among his latest patents, two standout innovations demonstrate Kole's expertise in designing targeted therapeutics. The first patent involves Oligonucleotide analogues targeting human LMNA, specifically addressing aberrantly spliced LMNA mRNA isoforms encoding progerin. The second patent focuses on a novel compound and method for treating myotonic dystrophy, wherein an antisense compound targets the pathological repeats in the DMPK mRNA associated with DM1 and DM2.
Career Highlights:
Kole's career trajectory showcases his commitment to advancing RNA-targeted therapies. With affiliations at renowned institutions such as Sarepta Therapeutics, Inc. and the University of Maryland, he has spearheaded groundbreaking research in the development of antisense compounds. His relentless pursuit of precision medicine has opened up new possibilities for treating complex genetic disorders.
Collaborations:
Collaborating with esteemed colleagues like Peter Sazani and Richard Keith Bestwick, Kole has fostered a culture of innovation and scientific excellence. Together, they have explored novel approaches to enhancing the efficacy and specificity of antisense oligonucleotides, paving the way for personalized medicine interventions in rare diseases.
Conclusion:
In conclusion, Ryszard M Kole stands as a visionary inventor who has revolutionized the landscape of molecular therapeutics. His dedication to harnessing the power of antisense technology underscores the transformative potential of precision medicine in addressing unmet medical needs. Kole's inventive spirit and collaborative ethos continue to inspire advancements in biopharmaceutical innovation, offering hope to patients and researchers alike.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile